You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
國藥現代(600420.SH):注射用頭孢曲松鈉(1.0g)通過一致性評價
格隆匯 05-27 18:25

格隆匯5月27日丨國藥現代(600420.SH)公吿,公司控股子公司國藥集團致君(深圳)製藥有限公司(“國藥致君”)近日收到國家藥監局核准簽發的注射用頭孢曲松鈉(1.0g)《藥品補充申請批准通知書》,批准該藥品通過仿製藥質量和療效一致性評價。

頭孢曲松鈉為長效、廣譜的第三代頭孢菌素類抗生素,臨牀上一般用於治療敏感菌所致的腦膜炎、腹部感染、骨和關節感染、皮膚和軟組織感染、包括淋病在內的生殖感染、腎臟和泌尿道感染以及術前感染等。

國藥致君注射用頭孢曲松鈉(1.0g)通過一致性評價將有利於該產品未來的市場銷售和市場競爭。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account